Patent 5,840,757 Landscape: Scope and Claims for US 5,840,757 (Essential-Fatty-Acid Lipid Emulsions) and US Exclusivity Risk

US Patent 5,840,757 claims lipid emulsions for parenteral or enteral foodstuff built around a defined long-chain fatty-acid profile: essential fatty acids limited to linoleic acid and α-linolenic acid at 15% to 45% by weight of total fatty acids, with a “consisting essentially of” lipid phase and 5% to 50% lipid phase in water. Dependent claims narrow the oil-mix embodiments into specific two-oil combinations (e.g., avocado/soybean; olive/soybean; avocado/walnut; olive/walnut) and add optional phospholipid emulsifiers and tonicity-regulating agents. The claim set also extends to compositions containing the lipid emulsion plus a solvent/adjuvant and optionally a pharmaceutically active ingredient, framed as dietetic compositions.

What does US Patent 5,840,757 claim protection cover for lipid emulsions (scope of independent claims)?

Short answer: The independent claim scope covers lipid emulsions (water-in-lipid and related injectable/enteral emulsion systems, as claimed generically) where the lipid phase is “essentially” a defined mixture of long-chain fatty acids, with essential fatty acids (linoleic and α-linolenic) comprising 15% to 45% of total fatty acids, and where the total emulsion contains 5% to 50% lipid phase by weight.

Claim 1 coverage mechanics (what must be in the product)

Claim 1 has four gating elements:

Product type and intended use framing
- “A lipid emulsion suitable for use as a parenteral or enteral foodstuff.”
- This is a use-context limiter. It still reads broadly as to formulation class (emulsion), but it targets nutritional lipid emulsions intended for parenteral/enteral feeding.
Composition ratio
- 5% to 50% by weight of the emulsion is lipid phase in water.
Lipid phase fatty-acid composition
- Lipid phase “consists essentially of” a mixture of long-chain fatty acids.
- Within that fatty-acid mixture, 15% to 45% by weight of the total fatty acids are essential fatty acids.
- The “essential fatty acids” are specifically linoleic acid and α-linolenic acid.
“Consisting essentially of” boundary
- “Consisting essentially of” allows additional ingredients only if they do not materially change the basic and novel characteristics of the claimed invention.
- Here, the basic characteristic is the defined long-chain fatty-acid composition distribution in the lipid phase (linoleic + α-linolenic totaling 15–45% by weight of total fatty acids, excluding other essential fatty acids from the definition).

Claim 16 coverage mechanics (near-duplicate but different structural framing)

Claim 16 is largely parallel to Claim 1 but re-states the lipid-phase structure as:

“lipid phase that comprises a mixture of at least two oils in water”
and the same fatty-acid constraints (15–45% essential fatty acids, linoleic + α-linolenic).

This means Claim 16 can support arguments that the emulsion is specifically oil-based and at least two oils are part of the lipid-phase system, while Claim 1 can be argued as more lipid-phase fatty-acid composition focused.

Key claim construction leverage points for freedom-to-operate and infringement

Percent of essential fatty acids (15–45%) is the core numerical limitation.
Identity of essential fatty acids is fixed to linoleic (18:2) and α-linolenic (18:3).
Lipid phase “consists essentially of” means formulation variants that introduce additional lipid-phase fatty-acid components that shift the essential fatty-acid fraction beyond 15–45%, or materially alter the fatty-acid profile, are outside literal scope.
Emulsion lipid-phase fraction (5–50%) is a second numerical boundary that can be used to carve out low-lipid admixtures or high-concentration lipid products.

How narrow are the dependent claims (oil-mix embodiments) in US 5,840,757?

Short answer: Dependent claims 2–9 lock in specific two-oil lipid-phase recipes with specified “by weight” percentages of each oil. If an accused product matches those oil ratios and also meets the essential-fatty-acid fraction requirements, the dependent claim embodiments are directly in play.

Claim 2 oil-family limitation

Claim 2 narrows the lipid phase to “a mixture of two or more oils selected from” a defined list of oils (apricot, almond, groundnut, avocado, wheat, safflower, rapeseed, coconut, cottonseed, lupin, maize, hazelnut, walnut, olive, oenothera, palm, palm-kernel, peach, grape, rice, rye, sesame, soybean, sunflower, tomato, linseed, citrus oils).

For analysis, Claim 2 is important because it:

Provides a closed list of oils for the multi-oil aspect.
Still leaves dependent embodiments to specify particular two-oil mixes in claims 3–9.

Claims 3–9: specifically enumerated two-oil embodiments

These dependent claims specify oil proportions “by weight” within the lipid phase:

Claim	Lipid phase oil mixture (by weight)	Two-oil pairing
3	~46% avocado oil + ~54% soybean oil	Avocado/soybean
4	~47% olive oil + ~53% soybean oil	Olive/soybean
5	~60% avocado oil + ~40% walnut oil	Avocado/walnut
6	~89% avocado oil + ~11% walnut oil	Avocado/walnut (high avocado)
7	~11% walnut oil + ~89% olive oil	Olive/walnut (high olive)
8	~85% olive oil + ~15% soybean oil	Olive/soybean (high olive)
9	~40% walnut oil + ~60% olive oil	Olive/walnut (balanced)

Analytical implications:

These are comparatively narrow embodiments. Many commercial lipid emulsions may use triglyceride blends or standardized structured lipids rather than “oil-to-oil” blends at these exact ratios.
The key for infringement is whether the accused product uses the same oil pair and ratio in the lipid phase (and still satisfies claim 1’s essential fatty-acid fraction).

Practical point: “by weight” oil ratios vs fatty-acid fraction

Even if an accused formulation uses oils similar to those listed, non-matching oil ratio can avoid dependent claims. But claim 1 can still read if the fatty-acid composition constraints are met independent of oil identity, subject to the “consists essentially of” boundary.

What formulation elements expand coverage in US 5,840,757 (phospholipid emulsifiers, tonicity agents, solvents/adjuvants)?

Short answer: Claims 10–12 add optional functional classes. Claims 13–15 broaden into “emulsion or solution” compositions containing the claimed lipid emulsion plus adjuvants and optionally a pharmaceutically active ingredient and/or dietetic composition framing.

Claim 10: phospholipids as emulsifiers

Adds: 0.5% to 5% by weight of the emulsion of plant, animal or synthetic phospholipids.
This is a formulation-specific dependent limitation. An accused product without phospholipids in that band can still fall under claim 1 if claim 1 alone is met, but claim 10 would not.

Claim 11–12: tonicity-regulating agents

Adds a tonicity-regulating agent.
Claim 12 defines selection: glycerol, glucose, a polyol, or an amino acid.

Again, these are dependent limitations: absence or out-of-range tonicity agent selection supports non-infringement of claims 11–12, but not necessarily independent claim 1.

Claim 13–15: compositions including solvent/adjuvant and optional API

Claim 13: “An emulsion or solution comprising a lipid emulsion as defined in claim 1 and a solvent or adjuvant.”
Claim 14: the emulsion/solution contains a pharmaceutically active ingredient.
Claim 15: the emulsion/solution is a dietetic composition.

Scope consequence: Claims 13–15 can potentially cover drug-loaded nutritional emulsions where the lipid emulsion meets claim 1 and the final product includes an API. The claims do not specify the API identity, delivery route, stability profile, or whether the “emulsion or solution” is the same physical form as the lipid emulsion (they read to include broader formulation contexts).

How do “consisting essentially of” and the essential-fatty-acid definition constrain infringement risk?

Short answer: The claims hinge on a defined essential fatty-acid content within the long-chain fatty-acid mixture and use “consisting essentially of” language to restrict what additional lipid-phase components can be present without materially altering the invention’s basic characteristic.

Essential fatty acids: definition by identity

“Essential fatty acids being linoleic acid and α-linolenic acid.”
This is narrower than a generic “omega-6 and omega-3” approach because it explicitly defines the two acids.

Essential fatty acids: definition by range

Total essential fatty acids must be 15% to 45% by weight of total fatty acids in the lipid phase’s long-chain fatty-acid mixture.
If an accused formulation has too little or too much linoleic plus α-linolenic relative to other fatty acids, it can fall outside claim 1 even if it uses the same oils.

“Consisting essentially of” affects permissible additions

A product can still have:

phospholipids (if used, claim 10 addresses that, but claim 1’s “consisting essentially of” could still allow emulsifiers if they do not materially change the fatty-acid profile).
tonicity agents (claims 11–12 define some classes). But additions that change the lipid phase basic characteristics, like altering fatty-acid distribution so essential fatty acids leave the 15–45% band, are not captured by claim 1.

What oil types are allowed, and what is excluded, under US 5,840,757?

Short answer: Allowed oils are limited to the Claim 2 list. Exclusion works through:

the oil list limitation in dependent claim 2,
and the fatty-acid fraction limitation in independent claim 1.

Allowed oil list (Claim 2)

The claim includes oils such as avocado, soybean, olive, walnut, safflower, rapeseed, cottonseed, sesame, sunflower, linseed, oenothera, palm, palm-kernel, etc., with fruits/nuts and plant-derived categories.

Exclusion path

A formulation using oils not on the Claim 2 list might still avoid dependent claims but could still potentially fall under claim 1 if claim 1 is satisfied without reliance on claim 2.

How does US 5,840,757 compare with typical nutritional lipid emulsion patent strategies (what would likely be next in an estate)?

Short answer: The patent is anchored in compositional numerical ranges and fatty-acid identity, rather than in delivery device, surfactant system alone, or process-only claims. That tends to create a patent landscape where:

many competitors can design around by changing fatty-acid distributions or lipid fraction,
while follow-on patents focus on specific emulsifier systems, structured lipids, or method/process and stability claims.

Given the specific claim drafting, the likely “next layers” in the broader landscape (not enumerated by this provided claim text) are typically:

emulsifier systems and droplet-size/stability parameters,
structured triglycerides or metabolic targeting,
methods of preparing or sterilizing lipid emulsions,
combinations with vitamins, trace elements, or therapeutic APIs.

What generic entry risks exist for lipid emulsions if US 5,840,757 is enforced?

Short answer: “Generic” risk is primarily a composition overlap risk rather than an ANDA-style identical-copy risk. If an entrant matches claim 1’s essential-fatty-acid range and lipid fraction, literal infringement becomes plausible. If an entrant stays outside the essential-fatty-acid fraction or the 5–50% lipid-phase fraction, claim 1 can be avoided while still using similar oils.

Design-around levers visible from the claim text

Adjust fatty-acid distribution so linoleic + α-linolenic falls outside 15–45% of total fatty acids.
Adjust lipid phase concentration so total lipid phase is outside 5–50% by weight.
If targeting dependent claims, avoid the specific oil pairs and ratios in claims 3–9.
Avoid phospholipid content in the 0.5–5% band (to avoid claim 10) and avoid the named tonicity agents (to avoid claims 11–12).
If asserting around claims 13–15, avoid using a lipid emulsion that meets claim 1’s constraints, regardless of API inclusion.

Key Takeaways

Core claim 1: lipid emulsions with 5–50% lipid phase in water, where the long-chain fatty acids in the lipid phase have 15–45% linoleic acid + α-linolenic acid as total fatty acids; lipid phase is “consisting essentially of” that fatty-acid mixture.
Core claim 16: similar constraints with an added structural framing of at least two oils in the lipid phase.
Dependent claims 2–9: narrow into specified two-oil combinations and ratios (avocado/soybean; olive/soybean; avocado/walnut; olive/walnut).
Dependent claims 10–12: optional emulsifier and tonicity agent classes (phospholipids 0.5–5%; tonicity agents including glycerol, glucose, polyols, amino acids).
Claims 13–15: extend the lipid emulsion into broader emulsion/solution formulations with solvents/adjuvants and optional pharmaceutically active ingredients and dietetic framing.
Enforcement and design-around: the highest-yield infringement/dismissal lever is whether linoleic plus α-linolenic equals 15–45% of total fatty acids in the lipid phase under the “consisting essentially of” boundary.

FAQs

What fatty-acid analytical method would be used to verify the 15–45% essential fatty-acid requirement in US 5,840,757?
Does “consisting essentially of” in claim 1 still allow additional oils outside the Claim 2 list?
Can a formulation avoid dependent claims 3–9 by using different oil ratios while still meeting the claim 1 essential fatty-acid range?
If a product contains a tonicity-regulating agent outside glycerol/glucose/polyol/amino acids, does it still risk infringement of claim 1?
For API-loaded nutritional emulsions, do claims 13–15 create additional infringement exposure beyond claim 1?

References

US Patent 5,840,757, “Lipid emulsions suitable for use as parenteral or enteral foodstuff,” claims provided in prompt.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	87 10407	Jul 23, 1987

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0302769	⤷ Start Trial	SPC/GB98/039	United Kingdom	⤷ Start Trial
European Patent Office	0302769	⤷ Start Trial	98C0036	Belgium	⤷ Start Trial
European Patent Office	0302769	⤷ Start Trial	C980014	Netherlands	⤷ Start Trial
Austria	65024	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,840,757

Summary for Patent: 5,840,757